文献速递瓣膜外科冠心病外科

经导管主动脉瓣置换术后非急诊心脏手术的指征与结局

Indications and Outcomes of Non-Emergent Cardiac Surgery Following Transcatheter Aortic Valve Replacement.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2026-01-01

单中心分析2011年8月至2023年9月61例TAVR后接受心脏手术的患者,分为SAVR组(n=33)与非SAVR组(n=28)。TAVR至手术中位间隔19个月,手术死亡率6.6%,1年与5年生存率分别为83%和50%。

要点

  • TAVR后SAVR主要指征为感染性心内膜炎与非结构性瓣膜衰败(各36%)。
  • 非SAVR手术主要处理二尖瓣疾病(43%)与冠心病(29%)。
  • TAVR后心脏手术复杂但死亡率可接受,需在TAVR规划时关注非主动脉瓣病变。

核心结论

  • TAVR后心脏手术虽复杂,但可达到可接受的死亡率。
  • SAVR主要指征为结构性瓣膜衰败、瓣周漏和心内膜炎,非SAVR以二尖瓣与冠心病为主。
  • TAVR规划时应考虑非主动脉瓣病变,尤其面向年轻低危人群扩展时。

研究设计与样本

  • 单中心回顾性分析,纳入2011年8月至2023年9月TAVR后接受心脏手术的61例患者。
  • 排除围术期并发症与分期手术,分为SAVR组(n=33)与非SAVR组(n=28)。
  • 数据来自前瞻性维护的心血管外科数据库与电子健康记录,生存用Kaplan-Meier评估。

主要发现

  • TAVR至心脏手术的中位间隔为19个月。
  • SAVR指征包括感染性心内膜炎(36%)、非结构性瓣膜衰败(36%)、结构性瓣膜衰败(12%)和瓣膜血栓(6%)。
  • 非SAVR手术主要针对二尖瓣疾病(43%)和冠心病(29%)。
  • 手术死亡率为6.6%,感染性心内膜炎亚组无死亡。
  • 术后并发症包括延长机械通气(18%)、新发肾衰竭(7%)和卒中(2%)。

关键数值与推荐

  • Kaplan-Meier生存估计1年为83%,5年为50%。
  • 手术死亡率为6.6%,感染性心内膜炎亚组无死亡。

临床怎么用

  • TAVR术后出现瓣膜衰败、瓣周漏、心内膜炎或合并二尖瓣病、冠心病时应评估再次心脏手术。
  • TAVR术前规划需评估并记录非主动脉瓣病变,以便后续随访与干预决策。

局限性

  • 单中心回顾性研究,样本量61例,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study examined the indications, frequency, and outcomes of cardiac surgery following transcatheter aortic valve replacement (TAVR) at a single institution. As TAVR volumes increase, understanding the nature and outcomes of subsequent cardiac operations is critical, particularly as the procedure expands to younger, lower-risk populations. METHODS: We analysed outcomes of 61 patients who underwent cardiac surgery after TAVR at our institution from August 2011 to September 2023, excluding periprocedural complications and staged procedures. Patients were stratified into 2 groups: those requiring surgical aortic valve replacement (SAVR) with or without concomitant procedures (n = 33) and those undergoing non-SAVR cardiac operations (n = 28). Data were collected from a prospectively maintained cardiovascular surgery database and electronic health records. Indications for surgery, operative characteristics, and outcomes were analysed, with survival assessed using Kaplan-Meier estimates. RESULTS: The median interval between TAVR and cardiac surgery was 19 months. Indications for SAVR included infective endocarditis (36%), non-structural valve deterioration (36%), structural valve deterioration (12%), and valve thrombosis (6%). Non-SAVR operations primarily addressed mitral valve disease (43%) and coronary artery disease (29%). Operative mortality was 6.6%, with no deaths in the endocarditis subgroup. Postoperative complications included prolonged mechanical ventilation (18%), new-onset renal failure (7%), and stroke (2%). Kaplan-Meier survival estimates were 83% at 1 year and 50% at 5 years. CONCLUSIONS: Although complex, cardiac operations in patients who have undergone TAVR can be performed with acceptable mortality rates. Structural valve deterioration, paravalvular leak, and endocarditis were the primary indications for SAVR, while mitral valve and coronary artery disease predominated in non-SAVR cases. These findings highlight the importance of considering nonaortic valve pathologies in TAVR planning, particularly as the procedure expands to younger, lower-risk populations.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Qamar Y, Schaff HV, Greason KL, et al. Indications and Outcomes of Non-Emergent Cardiac Surgery Following Transcatheter Aortic Valve Replacement. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42231119. doi:10.1093/icvts/ivag142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。